



A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on
Wednesday, 26th July 2023 via Microsoft Teams
MINUTE

Present: Dr Kevin Buchan (Chair ADTC and GP); Alison Wilson, Director of Pharmacy (AW); Liz Leitch, Formulary Pharmacist (LL); Dr Nicola Henderson, GP (NH); Dr Ed James, Consultant Microbiologist (EJ); Malcolm Clubb, Lead Pharmacist Community Pharmacy (MC); Cathryn Park, Senior Clinical Pharmacist (CP); Keith Maclure, Lead Pharmacist (KMacl); Dr Sohail Bhatti, Director of Public Health (SB); Kate Warner, Meeting Administrator (KW)

| Item | Situation ; Background; Assessment | Recommendation | Lead | Timescale |
|------|---|---|-------------|------------|
| 1. | Welcome and Announcements: Apologies: Dr Effie Dearden, DME Consultant; Andrew Leitch, Lay Member; Rhona Morrison, Medicines Governance/NMP Lead (RM) | | | |
| 2. | Declarations of Interest: None | | | |
| 3. | DRAFT Minute previous meeting | | | |
| 3.1 | Draft minute from 24 th May 2023 meeting were approved with no changes as an accurate record of the meeting. | Remove draft, pdf for internet/intranet | KW | 27/07/2023 |
| 4. | Matters Arising | | | |
| 4.1 | At May ADTC, the removal of Tramadol, Pregabalin and Dihydrocodeine from the East Region Formulary was discussed. It was agreed that an NFR would not be requested for prescribing with prescribers to consider all formulary options prior to commencing pregabalin (unless for epilepsy), dihydrocodiene or tramadol; and with a plan for review documented and discussed with the patient. An audit to be carried out for NHS Borders to establish a downward trend in prescribing. review appropriate prescribing and any action required. Use will be audited over the year ahead with results to be presented at ADTC in 12 months' time. | July 2024 Agenda | KMacl KW | 01/07/2023 |
| 4.2 | Steroid safety bundle – request for clarification from Dr R Williamson was not available. | September Agenda | KW | 19/09/2023 |
| 5. | NEW MEDICINE APPLICATIONS / NON FORMULARY REQUESTS: | | | |

| | | | | |
|-----------|--|--|-----------------|------------------------------|
| 5.1 | NFR Panel decisions made since last ADTC meeting: Fortisip – May 2023; Riboflavin June 2023; IVIG June 2023; Pancrex v powder July 2023. | ADTC Noted | | |
| 6. | PATIENT & MEDICINES SAFETY: | | | |
| 6.1 | Patient and Medicines Safety Update – Datix Review to July 2023 showed similar recurring themes to previous reports. Secondary care work-streams are work in progress along with regular audit data collection. Reporting is variable and the reports can only show what has been reported. Datix reports in primary care was discussed. It was agreed that the software is not easy to use nor lend itself to easily locating the correct drop down; often not all incidents of the same error are reported. Majority of use in primary care is NHS employees. In community pharmacy, they have their own system and this is not shared with NHS; resulting in another missing piece of the data. Clinical Governance and ADTC are aware that not all errors will be reported; Pharmacy review Datix reports weekly and aim to do regular staff awareness/education. If practice pharmacist training was required, this could be provided. ADTC agreed that this was not providing an accurate picture of errors and should be discussed at a higher level. | ADTC Noted Discuss at Board level. | SB | 19/09/2023 |
| 7. | CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL: | | | |
| 7.1 | Yellow Fever PGD was tabled for approval as part of the vaccine transformation programme. Travel vaccines are available through the hub and there is a suite of PGDs available with just Yellow Fever missing. The PGD has been adapted from a combination of NHS GG&C and Lothian. NHS Borders is registered as a yellow fever centre and we need the PGD to administer this private vaccination. | ADTC Approved To be signed off by directors and then included on intranet | KW | 31/07/2023 |
| 7.2 | NHS Borders Accountable Officer Controlled Drug Governance Annual Report 2022-23 was tabled for approval. Information included in this annual report comes from Datix. ADTC noted incidents regarding oxycodone and morphine confusion; ongoing education is required as incidents continue to occur. Other Boards report similar. Pharmacy are working with wards on daily CD checks; the Omnicell system has identified discrepancies in stock but this takes time to investigate due to the lack of daily checks. ADTC discussed Diazepam 2mg vs 5mg and 10mg; ERF has no 10mg on formulary and in Borders only 2mg should be prescribed. It was agreed that GPs present never prescribe more than 2mg and that any higher prescription would be specialist decision/reasonable use; BAS is same with patients requiring higher dose being on multiple of 2mg; reviews would be necessary. ADTC approved that prescribers should only prescribe 2mg tablets KMacI will include this information in the Prescribing Bulletin and Scriptswitch. ADTC approved the AOCD Annual Report. | ADTC Approved ADTC Approved Change to only 2mg of Diazepam Prescribing Bulletin Notify Community Pharmacy that there should be no 5mg or 10mg in stock | KMacI MC | 31/07/2023 31/07/2023 |
| 7.3 | NHS Borders Pharmacy Annual Report 2022-23 summarises the work of Pharmacy governance throughout the year. This year's themes covered work done on the National Prescribing Strategies – Chronic Pain, Mental Health and Polypharmacy. This report will go to Clinical Governance Committee in August. | ADTC Approved To CCG for August meeting; and publish to web | KW | 31/07/2023 |

| | | | | |
|-----|--|--|----------------------|--------------------------|
| 7.4 | NHS Borders Thematic Review 01/01/2019 – 31/12/2022. ADTC discussed the scope of the thematic review which is based on Datix incidents. There are a number of regular themes – DOACs, CDs and Insulin. Pharmacy will be able to look at these in more detail when we have more staff on wards; this will enable ADTC to review where support may be needed. ADTC agreed that it would be useful to have more information from primary and community, not just acute. Primary care and community pharmacy do their own significant event analysis for their own governance. Sharing of event information would be possible with electronic prescribing (HEPMA) which NHS Borders does not have. HEPMA would mean easier access to data between primary and secondary care. Concern for risk; particularly in older population. Other ways to capture data were discussed including polypharmacy reviews to build intelligence. During Covid, polypharmacy reviews were not priority and how care is delivered in primary care has changed dramatically since then. There has been an increase in the volume of prescriptions and patients attending practices. HEPMA has been included in the medium term plan and will go back to NHS Borders Board next year; it is at least two years off. | September agenda – full report from RM | KW RM | 19/09/2023 |
| 7.5 | NHS Borders Non-Medical Prescribing Policy update has all minor amendments marked as tracked changes until approved. There are some other yellow highlighted items which require advice from ADTC. This will be emailed to ADTC members with a request to review and respond to RM. The policy can then be updated and approved. | Email to ADTC with request to respond to RM | KW | 31/07/2023 |
| 7.6 | Instilagel PGD was approved as an extension till end July 2023 and with the update not being ready for July agenda, ADTC agreed that this should be extended until 1 st October 2023 and return to ADTC September meeting, with any changes in change log, for approval going forward. | ADTC Approved extension to October Updated PGD - September agenda | KW RM/KW | 31/07/2023 19/09/2023 |
| 8. | FOR INFORMATION and NOTING: | | | |
| 8.1 | East Region Formulary updates 1) ERF Committee minute – 7 June 2023 included approval for Saxenda for weight loss indication; with information to be included in the next prescribing bulletin. Supply availability of this product was discussed; to be included in Bulletin along with local guidance issued from Endocrinology. 2) ERWG minute – 17 May 2023 – included gender reassignment prescribing to be discussed at item 8.2 and request for Boards to have plans in place regarding the removal of Tramadol, Pregabalin and Dihydrocodeine from East Region Formulary; this will be communicated to GPs. 3) Flyer announcing ERF Launch which includes App download, how to use and other relevant information. | ADTC Noted ERF Launch Flyer to be emailed to all prescribers. | KW/LL KMacI MC | 31/07/2023 |
| 8.2 | ERF Chapter Updates – ADTC notes that all updates to Chapters are included on website with links to ERF. A new pathway for prescribing in gender reassignment is currently in draft form and primary care colleagues were asked for their opinion on the requirement of a shared care protocol. This was discussed and ADTC agreed that a shared care agreement requires work and interaction between specialist and primary care and that if the decision is specialist | ADTC Noted ERWG update | LL | |

| | | | | |
|-----------|--|----------------------------------|-------|------------|
| | it does not require the shared care. Specialist decision with prescribing by GP and no monitoring required by GP is how this currently works and so no requirement for shared care protocol. This response can be shared with ERF chapter group. | | | |
| 8.3 | Borders Joint Formulary to East Region Formulary – ADTC reviewed the summary of main changes and abbreviated version which includes specialist drugs in main changes document and every day formulary changes in the abbreviated version. ADTC agreed this was a useful document and that it can be used for updating EMIS and Scriptswitch as well as used in formulary teaching. It was agreed that use of East Region Formulary should be promoted again with links to information included in the Prescribing Bulletin and sent to all prescribers. Removal of Tramadol, Pregabalin and Dihydrocodeine prescribing has been supported by Primary Care Prescribing Group, GP Sub, Clinical Directors and now ADTC. In NHS Borders, we will not be requesting NFRs for prescribing of these drugs; decline of prescribing will be reviewed in future. | ADTC Noted | | |
| | SB left at this point in the meeting. | | | |
| 8.4 | PSS Clinical Guidelines update - bowel preparation products used in the colon capsule endoscopy service (CCE) in Scotland (ScotCap). | ADTC Noted Discuss GI service | LL/CP | |
| 8.5 | MHRA Drug Safety Alert – May 2023; main highlights were covered; to discuss with RM and other services as appropriate. In the June update, ADTC noted there was information on the use of IV calcium chloride and potential risk of under dosing in hyperkalaemia; consultants have been updated and Lothian guidance is expected which will inform NHS Borders guidance and will come to ADTC for approval. | ADTC Noted | | |
| 8.6 | ADTC Collaborative Newsletter – July 2023 | ADTC Noted | | |
| 8.7 | SIGN 166 National Clinical Guideline for Stroke for UK & Ireland. Reported that this should go to Anti-Coagulation Committee as there is an action, related to andexanet alfa, included for that committee to review. | ADTC Noted F/wd to Anti-Coag | KW | 31/07/2023 |
| 8.8 | NCMAG Quarterly Updates – June and July 2023. ADTC do not need to review this recurring item as it is reviewed regionally. | ADTC Noted Remove item | KW | 19/09/2023 |
| 9. | FEEDBACK from SUB GROUPS | | | |
| 9.1 | Anticoagulation Committee minute from meeting held 12 th June 2023. Reported lack of representatives from different specialities; RM to advise if ADTC can help with recruitment. | ADTC Noted | | |
| 9.2 | Antimicrobial Management Team meeting 19 th July 2023 – minute was not available. Reported there is an updated work-plan which will come to ADTC for noting when available. | ADTC Noted | | |
| 9.3 | Controlled Drug Governance Team – this meeting is held on a 6 weekly basis as a catch up for the CD team and there are no minutes. There is an East Region LIN meeting whose minutes can be shared if required. | Remove agenda item | KW | 19/09/2023 |
| 9.4 | IV Therapy Group minute from meeting held 10 th May 2023 | ADTC Noted | | |

| | | | | |
|---|--|------------|--|--|
| 9.5 | Medicines Resource Group minute from meeting held 28 th June 2023. Reported an increase in costs and emphasis on polypharmacy reviews to deliver savings and outliers being reviewed. | ADTC Noted | | |
| 9.6 | Non-Medical Prescribing Group – no recent meeting | | | |
| 9.7 | Tissue Viability Steering Group - no recent minute | | | |
| 9.8 | NHS Lothian ADTC minute from meeting held 14 th April 2023 | ADTC Noted | | |
| 10. | AOCB | | | |
| 10.1 | | | | |
| Date and time of next meeting: Wednesday 27th September 2023 at 12:30pm via Microsoft Teams. | | | | |
| Items expected for future Agendas – Unlicensed Medicines Approval Process (September 2023); Public Private Policy (September 2023) | | | | |